AT Impf

AT Impf is a venture capital firmventure capital firm in Munich, Germany that invests in the biotechnology and pharmaceutical sectors. Founded 2010 in Munich, Bayern, Germany, this venture capital company invests in Series C, Series D, Series E and other venture rounds. Its portfolio companies include Isarna Therapeutics and immatics biotechnologies. As of February 2020, AT Impf venture capital firm has made five investments. Their most recent investment was on Oct 4, 2017, when immatics biotechnologies raised $58M.

AT Impf is a venture capital firm in MunichMunich, Germany that invests in the biotechnology and pharmaceutical sectors. Founded 2010 in Munich, Bayern, Germany, this venture capital company invests in Series C, Series D, Series E and other venture rounds. Its portfolio companies include Isarna Therapeutics and immatics biotechnologies. As of February 2020, AT Impf venture capital firm has made five investments. Their most recent investment was on Oct 4, 2017, when immatics biotechnologies raised $58M.

AT Impf is a venture capital firm in Munich, GermanyGermany that invests in the biotechnology and pharmaceutical sectors. Founded 2010 in Munich, Bayern, Germany, this venture capital company invests in Series C, Series D, Series E and other venture rounds. Its portfolio companies include Isarna Therapeutics and immatics biotechnologies. As of February 2020, AT Impf venture capital firm has made five investments. Their most recent investment was on Oct 4, 2017, when immatics biotechnologies raised $58M.

AT Impf is a venture capital firm in Munich, Germany that invests in the biotechnology and pharmaceutical sectors. Founded 2010 in Munich, Bayern, Germany, this venture capital company invests in Series C, Series D, Series E and other venture rounds. Its portfolio companies include Isarna Therapeutics and immatics biotechnologies. As of February 2020, AT Impf venture capital firm has made five investments. Their most recent investment was on Oct 4, 2017, when immatics biotechnologies raised $58M.